No Data
Mizuho Securities Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $90
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Daily short sale tracking: Warner Bros Discovery's short volume increased by 4 million, with a short sale ratio of 16%
Marengo Therapeutics Enters Clinical Study Collaboration And Supply Agreement With Gilead Sciences
Express News | Marengo Therapeutics: Under Agreement, Gilead Will Provide Trodelvy to Marengo
Marengo Therapeutics Announces Clinical Study Collaboration With Gilead Sciences to Evaluate Invikafusp Alfa (STAR0602) and Trodelvy in Both Metastatic TNBC and Metastatic HR+/HER2- Breast Cancers